The Drug Triad That Could Overwhelm Plans

The Drug Triad That Could Overwhelm Plans

March 30, 2021 8:00 AM to 9:00 AMOnline - PST
Area of Interest: Benefits Format: Web

From One, to Some, to Many: Gene Therapies, Cancer Drugs, Diabetes Drugs, The Drug Triad That Could Overwhelm Plans  

 
Reformulary Group CEO and former Ontario ‘drug czar’ Helen Stevenson joins CPBI to talk about new and existing therapies that could overwhelm employer benefit plans – gene therapies, cancer drugs and diabetes treatment. Would it surprise you to know that a gene therapy costing more than $2.8 million per patient has recently been approved in Canada, or that some private plans are paying claims for cancer drugs that are typically covered by cancer agencies? As more and more expensive drugs roar up the regulatory pipeline, understanding their cost and how plans can be informed and manage their impact has never been more important.

   

SPEAKER  

   

 

Helen Stevenson, B.Comm., M.Sc., ICD.D,
Founder and CEO - Reformulary Group Inc.


  

CE Credit: Certificates of Attendance confirming education hours will be offered, with which attendees may seek corresponding accreditation via their preferred regulatory body.

We hope to see you there !

Are you attending several sessions? It may be worth it to renew or to get a membership.

Comments? Questions? Email us! 
CPBI Pacific Region 
[email protected] 


THANK YOU TO OUR SPONSORS

REGISTRATION FEES

Category
Price
CPBI Member   
$25.00 CDN
Non Member$75.00 CDN
 
Cancellation Policy
CE Credit: Certificates of Attendance confirming education hours will be offered, with which attendees may seek corresponding accreditation via their preferred regulatory body.
By continuing to use this website, you are agreeing to our use of cookies.